EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer

Jair Bar; Arnold Cyjon; Dov Flex; Hadas Sorotsky; Haim Biran; Julia Dudnik; Nili Peylan-Ramu; Nir Peled; Hovav Nechushtan; Maya Gips; Rivka Katsnelson; Shoshana Keren Rosenberg; Ofer Merimsky; Amir Onn; Maya Gottfried

doi:10.1007/s00408-014-9604-7

EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer

Jair Bar^*, Arnold Cyjon, Dov Flex, Hadas Sorotsky, Haim Biran, Julia Dudnik, Nili Peylan-Ramu, Nir Peled, Hovav Nechushtan, Maya Gips, Rivka Katsnelson, Shoshana Keren Rosenberg, Ofer Merimsky, Amir Onn, Maya Gottfried

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Purpose: Testing tumor samples for the presence of a mutation in the epithelial growth factor receptor (EGFR) gene is recommended for advanced non-squamous non-small cell lung cancer (NSCLC) patients. We aimed to collect data about common practice among Medical Oncologists treating lung cancer patients, regarding EGFR mutation testing in advanced NSCLC patients. Methods: An internet-based survey was conducted among members of the Israeli Society for Clinical Oncology and Radiotherapy involved in the treatment of lung cancer patients. Results: 24 Oncologists participated in the survey. The participants encompass the Oncologists treating most of the lung cancer patients in Israel. 79 % of them use EGFR testing routinely for all advanced NSCLC patients. Opinions were split regarding the preferable biopsy site for EGFR testing material. 60 % of participants recommend waiting for EGFR test results prior to initiation of first-line therapy. Conclusions: EGFR testing is requested in Israel routinely by most treating Oncologists for all advanced NSCLC patients, regardless of histology. In most cases, systemic treatment is deferred until the results of this test are received.

Original language	English
Pages (from-to)	759-763
Number of pages	5
Journal	Lung
Volume	192
Issue number	5
DOIs	https://doi.org/10.1007/s00408-014-9604-7
State	Published - 1 Oct 2014

Keywords

Biopsy site
Common practice
EGFR testing
NSCLC
Non-squamous

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00408-014-9604-7

Cite this

@article{1aa18870441f4c0aa03d2e2079af8a0d,

title = "EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer",

abstract = "Purpose: Testing tumor samples for the presence of a mutation in the epithelial growth factor receptor (EGFR) gene is recommended for advanced non-squamous non-small cell lung cancer (NSCLC) patients. We aimed to collect data about common practice among Medical Oncologists treating lung cancer patients, regarding EGFR mutation testing in advanced NSCLC patients. Methods: An internet-based survey was conducted among members of the Israeli Society for Clinical Oncology and Radiotherapy involved in the treatment of lung cancer patients. Results: 24 Oncologists participated in the survey. The participants encompass the Oncologists treating most of the lung cancer patients in Israel. 79 % of them use EGFR testing routinely for all advanced NSCLC patients. Opinions were split regarding the preferable biopsy site for EGFR testing material. 60 % of participants recommend waiting for EGFR test results prior to initiation of first-line therapy. Conclusions: EGFR testing is requested in Israel routinely by most treating Oncologists for all advanced NSCLC patients, regardless of histology. In most cases, systemic treatment is deferred until the results of this test are received.",

keywords = "Biopsy site, Common practice, EGFR testing, NSCLC, Non-squamous",

author = "Jair Bar and Arnold Cyjon and Dov Flex and Hadas Sorotsky and Haim Biran and Julia Dudnik and Nili Peylan-Ramu and Nir Peled and Hovav Nechushtan and Maya Gips and Rivka Katsnelson and Rosenberg, {Shoshana Keren} and Ofer Merimsky and Amir Onn and Maya Gottfried",

note = "Publisher Copyright: {\textcopyright} 2014, Springer Science+Business Media New York.",

year = "2014",

month = oct,

day = "1",

doi = "10.1007/s00408-014-9604-7",

language = "אנגלית",

volume = "192",

pages = "759--763",

journal = "Lung",

issn = "0341-2040",

publisher = "Springer New York",

number = "5",

}

TY - JOUR

T1 - EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer

AU - Bar, Jair

AU - Cyjon, Arnold

AU - Flex, Dov

AU - Sorotsky, Hadas

AU - Biran, Haim

AU - Dudnik, Julia

AU - Peylan-Ramu, Nili

AU - Peled, Nir

AU - Nechushtan, Hovav

AU - Gips, Maya

AU - Katsnelson, Rivka

AU - Rosenberg, Shoshana Keren

AU - Merimsky, Ofer

AU - Onn, Amir

AU - Gottfried, Maya

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Purpose: Testing tumor samples for the presence of a mutation in the epithelial growth factor receptor (EGFR) gene is recommended for advanced non-squamous non-small cell lung cancer (NSCLC) patients. We aimed to collect data about common practice among Medical Oncologists treating lung cancer patients, regarding EGFR mutation testing in advanced NSCLC patients. Methods: An internet-based survey was conducted among members of the Israeli Society for Clinical Oncology and Radiotherapy involved in the treatment of lung cancer patients. Results: 24 Oncologists participated in the survey. The participants encompass the Oncologists treating most of the lung cancer patients in Israel. 79 % of them use EGFR testing routinely for all advanced NSCLC patients. Opinions were split regarding the preferable biopsy site for EGFR testing material. 60 % of participants recommend waiting for EGFR test results prior to initiation of first-line therapy. Conclusions: EGFR testing is requested in Israel routinely by most treating Oncologists for all advanced NSCLC patients, regardless of histology. In most cases, systemic treatment is deferred until the results of this test are received.

AB - Purpose: Testing tumor samples for the presence of a mutation in the epithelial growth factor receptor (EGFR) gene is recommended for advanced non-squamous non-small cell lung cancer (NSCLC) patients. We aimed to collect data about common practice among Medical Oncologists treating lung cancer patients, regarding EGFR mutation testing in advanced NSCLC patients. Methods: An internet-based survey was conducted among members of the Israeli Society for Clinical Oncology and Radiotherapy involved in the treatment of lung cancer patients. Results: 24 Oncologists participated in the survey. The participants encompass the Oncologists treating most of the lung cancer patients in Israel. 79 % of them use EGFR testing routinely for all advanced NSCLC patients. Opinions were split regarding the preferable biopsy site for EGFR testing material. 60 % of participants recommend waiting for EGFR test results prior to initiation of first-line therapy. Conclusions: EGFR testing is requested in Israel routinely by most treating Oncologists for all advanced NSCLC patients, regardless of histology. In most cases, systemic treatment is deferred until the results of this test are received.

KW - Biopsy site

KW - Common practice

KW - EGFR testing

KW - NSCLC

KW - Non-squamous

UR - http://www.scopus.com/inward/record.url?scp=84931311648&partnerID=8YFLogxK

U2 - 10.1007/s00408-014-9604-7

DO - 10.1007/s00408-014-9604-7

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 24964874

AN - SCOPUS:84931311648

SN - 0341-2040

VL - 192

SP - 759

EP - 763

JO - Lung

JF - Lung

IS - 5

ER -

EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this